.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 9,295,642

« Back to Dashboard

Claims for Patent: 9,295,642

Title:Methylphenidate extended release chewable tablet
Abstract: An oral methylphenidate extended release tablet is described, which can be scored and still retain its extended release profile. The tablet contains a combination of an uncoated methylphenidate-ion exchange resin complex, a barrier coated methylphenidate-ion exchange resin complex-matrix, and an uncomplexed methylphenidate active component. Following administration of a single dose of the extended release methylphenidate chewable tablet, a therapeutically effective amount of methylphenidate is reached in less than about 20 minutes and the composition provides a twelve-hour extended release profile.
Inventor(s): Tu; Yu-Hsing (West Windsor, NJ), Perumal; Ashok (Monmouth Junction, NJ), Kathala; Kalyan (Monmouth Junction, NJ)
Assignee: Tris Pharma, Inc. (Monmouth Junction, NJ)
Application Number:14/872,226
Patent Claims: 1. An extended release racemic methylphenidate chewable tablet, wherein said chewable tablet is a uniform solid dispersion comprising: (a) a sustained release racemic methylphenidate component comprising a water-insoluble, water-permeable, pH-independent barrier coated, racemic methylphenidate-ion exchange resin complex in a polymeric matrix, wherein said barrier coating which provides a sustained release profile to the racemic methylphenidate is over the racemic methylphenidate-ion exchange resin complex-matrix; (b) a first immediate release component which comprises an immediate release uncoated racemic methylphenidate-ion exchange resin complex; (c) a second immediate release racemic methylphenidate component which comprises an uncomplexed racemic methylphenidate acceptable salt thereof; wherein said first immediate release component (b) has a slower onset of release than (c); wherein about 50% w/w to about 90% w/w of the racemic methylphenidate active component is provided by the sustained release component based on the total amount of racemic methylphenidate in the tablet, and wherein said chewable tablet is capable of being divided and providing tablet portions which retain a therapeutically effective extended release profile, and a pharmacokinetic profile in which the methylphenidate has at least one of: a geometric mean for area under the curve (AUC).sub.0-.infin. of about 110 ng-hr/mL to about 140 ng-hr/mL and a geometric mean C.sub.max of about 10 ng/mL to about 15 ng/mL, under fasted and fed conditions in adults following a single oral administration of a chewable tablet comprising the equivalent of 40 mg racemic methylphenidate HCl.

2. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein C.sub.max is about 12 ng/mL to about 13 ng/mL.

3. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein geometric mean AUC.sub.0-.infin. is about 113 ng-hr/mL to about 138 ng-hr/mL.

4. The extended release racemic methylphenidate chewable tablet according to claim 1, the sustained release methylphenidate component provides about 60% w/w to about 80% w/w of the methylphenidate in the chewable tablet, based on the total amount of methylphenidate in the tablet.

5. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the immediate release uncoated racemic methylphenidate-ion exchange resin complex (b) and immediate release uncomplexed racemic methylphenidate (c) together comprise 20% w/w to about 40% w/w of the total racemic methylphenidate in the chewable tablet.

6. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the ratio of the immediate release uncoated methylphenidate-ion exchange resin complex (b) to immediate release component uncomplexed methylphenidate (c) is in the range of about 3:1 based on the total weight of immediate release components.

7. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the immediate release racemic methylphenidate-ion exchange resin complex is about 5% w/w to about 35% w/w of the total racemic methylphenidate in the chewable tablet.

8. The extended release racemic methylphenidate chewable tablet according claim 1, wherein the immediate release uncomplexed racemic methylphenidate (c) is in the form of a pharmaceutically acceptable salt.

9. The extended release racemic methylphenidate chewable tablet according claim 8, wherein the immediate release uncomplexed racemic methylphenidate (c) is in the form of racemic methylphenidate HCl.

10. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the immediate release uncomplexed racemic methylphenidate (c) is about 5% w/w to about 35% w/w of the total racemic methylphenidate in the chewable tablet, based on a calculation of total racemic methylphenidate in the tablet.

11. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the tablet comprises immediate release methylphenidate-ion exchange resin complex of (b) is about 15% w/w of the racemic methylphenidate in the tablet and a faster onset immediate release uncomplexed racemic methylphenidate (c) in about 15% w/w, based on a calculation of total racemic methylphenidate in the tablet.

12. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the tablet has a hardness in the range of about 8 kp to about 23 kp.

13. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the water insoluble, water-permeable, pH-independent barrier coating has a tensile strength in a range of about 150% to about 400% and is selected from (a) a cured, water-permeable, non-ionic, pH-independent barrier coating comprising polyvinylacetate, a stabilizer, and a plasticizer, applied as an aqueous dispersion; (b) an ionic, pH-independent, acrylic based coating comprising a polymer or copolymer comprising ethyl acrylate and methyl methacrylate applied as an aqueous dispersion; and (c) a solvent-based ethylcellulose coating, optionally with a plasticizer.

14. The extended release racemic methylphenidate chewable tablet according to claim 13, wherein the barrier coating over the methylphenidate-ion exchange resin complex-matrix of (a) is a cured, water-insoluble, water-permeable, non-ionic, pH-independent barrier coating comprises about 70 to about 90% w/w polyvinylacetate, a stabilizer, and about 2 to about 10% w/w of a plasticizer.

15. The extended release racemic methylphenidate chewable tablet according to claim 14, wherein the barrier coating layer is about 25% to about 35%, by weight, of the coated racemic methylphenidate-ion exchange resin complex-matrix.

16. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the polymeric matrix comprises polyvinylpyrolidone.

17. The extended release chewable racemic methylphenidate tablet according to claim 1, wherein the polymeric matrix further comprises a water-insoluble polymer.

18. The extended release racemic methylphenidate chewable tablet according to claim 16, wherein the barrier coating over the methylphenidate-ion exchange resin complex-matrix of (a) has a pH-independent, acrylic based coating, which said coating comprises a blend of (i) a poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl methacrylate chloride) in a ratio of 1:2:0.1 and (ii) poly(ethyl acrylate-co-methyl methacrylate-co-trimethylammonioethyl methacrylate chloride) in a ratio of 1:2:0.2.

19. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the tablet further comprises a non-functional outer top coating layer.

20. The extended release racemic methylphenidate chewable tablet according to claim 1 which further comprises one or more excipients.

21. A method of providing a subject with therapeutically effective amount of racemic methylphenidate, said method comprising orally administering to said subject a single methylphenidate extended release chewable tablet according to claim 1.

22. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the chewable tablet has a pharmacokinetic profile for racemic methylphenidate comprising a single mean plasma concentration peak.

23. The extended release racemic methylphenidate chewable tablet according to claim 22, wherein the single mean plasma concentration peak is between about 4 hours to about 5.25 hours under fasted and fed conditions.

24. The extended release racemic methylphenidate chewable according to claim 1, wherein pharmacokinetic profile further comprises the 90% confidence intervals of the geometric mean test/reference ratios of one or more of AUC0-3 or AUC0-4 of FIG. 1.

25. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the AUC0-3 is bioequivalent to about 18 ng-hr/mL.

26. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein the methylphenidate plasma concentration, as determined under fasted and fed conditions following a single oral administration of said chewable tablet at a dose equivalent to 40 mg racemic methylphenidate HCl in adults, is equivalent to the plasma concentration curve of FIG. 1 from about 0 to about 8 hours.

27. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein said tablet comprises the equivalent of 40 mg racemic methylphenidate HCl.

28. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein said tablet comprises the equivalent of 20 mg racemic methylphenidate HCl.

29. The extended release racemic methylphenidate chewable tablet according to claim 1, wherein said tablet is scored.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc